ValiRx - US Patent Grant for VAL201
VAL
Thu, 11 Jan 2018, 07:10am GMT
ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.
Industry: Health Care
Contact: +44 (0)2476 796496
Barling Way
https://www.valirx.com/
ValiRx Plc, the clinical stage biotechnology company, is pleased to provide an update following the notification of the US patent grant allowance for the therapeutic compound, VAL201. The compound is currently in a Phase I/II study primarily assessing safety and tolerability of VAL201 and its effect in the treatment of prostate cancer and other solid tumours.
